By Ben Fidler | September 25, 2026
The biopharmaceutical landscape shifted significantly this week as major players grappled with the realities of drug development, judicial scrutiny, and regulatory milestones. From Novo Nordisk’s aggressive pursuit of long-acting injectable technology to a high-stakes courtroom verdict involving Nektar Therapeutics and Eli Lilly, the sector continues to demonstrate the volatility and high-reward potential inherent in modern medicine.
Main Facts: A Sector in Motion
This week has been characterized by a blend of long-term strategic alliances and immediate regulatory wins. The primary headlines include:
- Novo Nordisk’s Long-Acting Ambitions: In a move to consolidate its dominance in the cardiometabolic market, Novo Nordisk has entered into a massive licensing agreement with Swedish biotech Nanexa. The deal, valued at up to €1.165 billion ($1.32 billion), focuses on "PharmaShell" technology, designed to extend the dosing intervals of injectables for obesity and Type 2 diabetes.
- Acadia’s Alzheimer’s Gamble: Despite a "narrow miss" in Phase 2 clinical trials for its drug remlifanserin, Acadia Pharmaceuticals has committed to pushing forward into Phase 3 trials for Alzheimer’s disease psychosis, banking on the drug’s safety profile and the potential for better outcomes in larger cohorts.
- The Nektar vs. Lilly Verdict: A California federal jury delivered a verdict in the long-standing legal battle between Nektar Therapeutics and Eli Lilly. While the jury found in favor of Nektar regarding misconduct claims related to a failed autoimmune collaboration, the $90 million award fell drastically short of the nearly $1 billion the company had sought.
- Regulatory Milestones: The FDA issued two pivotal approvals: Eli Lilly’s once-weekly insulin, Onswik, providing a direct competitor to Novo’s Awiqli, and the expansion of Merck & Co.’s Welireg for relapsed kidney cancer.
Chronology of Events
The week’s events reflect a fast-moving industry where R&D and legal strategy collide:
- September 23-24: Market analysts began digesting the implications of the Nektar-Lilly legal proceedings, which originated from a 2023 lawsuit alleging that Lilly intentionally undermined an autoimmune drug development program following its acquisition of a rival therapy.
- September 25 (Thursday):
- Morning: The FDA announced the approval of Eli Lilly’s Onswik (once-weekly insulin) for Type 2 diabetes, intensifying the battle for the weekly-dosing market.
- Mid-day: A California jury delivered its verdict in the Nektar-Lilly case, concluding a multi-year legal saga.
- Afternoon: Acadia Pharmaceuticals’ share price saw double-digit declines as investors reacted to the mixed data regarding remlifanserin.
- Evening: Novo Nordisk confirmed its partnership with Nanexa, signaling a shift in how it plans to manage patient adherence for its flagship metabolic therapies.
- Ongoing: Merck & Co. received confirmation of an expanded label for Welireg, solidifying the drug’s position in its oncology portfolio.
Supporting Data and Technical Context
The "PharmaShell" Mechanism
Novo Nordisk’s partnership with Nanexa centers on the latter’s proprietary "PharmaShell" technology. This technology utilizes atomic layer deposition to coat drug molecules, essentially creating a protective shield that allows for a controlled, sustained release within the body. By moving from daily injections to once-monthly or once-quarterly doses, Novo aims to drastically reduce the "burden of care" for patients managing chronic conditions like obesity and Type 2 diabetes.
The Efficacy of Onswik
The FDA’s approval of Onswik is supported by extensive clinical data demonstrating that a once-weekly injection is non-inferior to traditional daily basal insulin. This is a critical development for patient quality of life. The entry of Onswik follows the March 2026 approval of Novo’s Awiqli, creating a "weekly-insulin" duopoly that is expected to reshape the standard of care for diabetes management.
Welireg Performance
Merck’s Welireg continues to be a commercial success story. Originally acquired from Peloton Therapeutics in 2019, the drug has successfully navigated multiple FDA approvals. With $470 million in sales in the first half of 2026 alone, the addition of a label for patients who have relapsed after Keytruda therapy significantly expands its target patient population.
Official Responses and Analyst Perspectives
The industry reaction to these developments has been mixed, reflecting the complex interplay between clinical success and market expectations.
On Acadia Pharmaceuticals:
Stifel analyst Paul Matteis provided a tempered view on the remlifanserin situation. While acknowledging the disappointment of the Phase 2 trial, he noted, "The debate is going to be whether there is still a chance that the drug will succeed in Phase 3. In our view, there is still a chance." However, he also highlighted that the trial was "very well-powered," making the modest efficacy findings a cause for genuine concern among institutional investors.
On Nektar Therapeutics:
Nektar, in a regulatory filing, noted that the $90 million verdict is subject to post-trial proceedings. The massive discrepancy between the requested damages and the final award highlights the difficulty in quantifying lost potential in collaborative drug development agreements. Lilly has remained relatively tight-lipped, focusing on its recent regulatory wins like Onswik.
Implications for the Future of Biopharma
1. The Era of Long-Acting Maintenance
The Novo-Nanexa deal is a harbinger of a broader trend: the "convenience war." As the metabolic market becomes increasingly crowded, the differentiator is no longer just the drug’s efficacy, but the administration frequency. If Novo can successfully transition its pipeline to quarterly injections, it will set a new competitive baseline that competitors will struggle to match.
2. Legal Precedent in Collaborative R&D
The Nektar-Lilly verdict serves as a cautionary tale for "Big Pharma" partnerships. It underscores the legal risks associated with acquiring competing technologies after entering a development alliance. Companies are now likely to adopt more rigorous "anti-cannibalization" clauses in their future licensing contracts to avoid similar litigation.
3. Regulatory Speed and Market Access
The back-to-back approvals for Onswik and the label expansion for Welireg demonstrate that the FDA remains highly efficient in processing applications for drugs that address unmet needs in chronic and oncological diseases. For Merck, the expansion of Welireg is a strategic masterstroke, ensuring the drug maintains relevance even as patients progress through different lines of therapy.
4. The High Cost of "Near Misses"
Acadia’s struggle with remlifanserin illustrates the "all or nothing" nature of CNS (Central Nervous System) drug development. When a company chooses to proceed with Phase 3 trials despite mixed mid-stage results, it faces intense scrutiny. The market’s double-digit negative reaction to Acadia’s announcement proves that investors are increasingly wary of "betting on the comeback" when the underlying data is perceived as statistically fragile.
Conclusion
As we move into the final quarter of 2026, the biopharma industry finds itself at a crossroads. The focus is shifting from simply discovering new molecules to optimizing delivery mechanisms and navigating the complex legal landscape of modern partnerships. Whether it is the battle for the weekly insulin market or the fight for survival in Alzheimer’s research, the next six months promise to be as transformative as they are unpredictable. Investors, patients, and regulators alike will be watching to see if these high-stakes gambles—from Nanexa’s tech to Acadia’s clinical persistence—ultimately pay off.
